This study was designed to compare both the effectiveness and safety of two low-dose gonadotrophin regimens (stepup versus sequential step-up and step-down) for ovulation induction in polycystic ovarian syndrome (PCOS) patients. In all, 56 infertile clomiphene citrate-resistant PCOS patients were included in this prospective randomized study. A total of 38 cycles were conducted with a classic stepup protocol, whereas for 35 cycles the follicle-stimulating hormone (FSH) threshold dose was reduced by half when the leading follicle reached 14 mm in diameter (sequential protocol). Serum oestradiol, progesterone and luteinizing hormone concentrations and follicular growth rate were evaluated during the cycle. At the time of human chorionic gonadotrophin administration, cycles treated with sequential protocol exhibited significantly lower oestradiol concentrations [434 ± 45 versus 593 ± 67 pg/ml (mean ± SEM)] and the number of medium-sized (14-15 mm) follicles was significantly reduced (03 ±0.1 versus 0.8 ± 0.2) compared with cycles treated with the classic step-up protocol. Moreover, in these cycles serum luteal oestradiol concentrations were decreased significantly (350 ± 77 versus 657 ± 104 pg/ ml) compared with the classic step-up protocol. A sequential step-up and step-down protocol seems to be a safe and effective regimen for ovulation induction in PCOS patients. Decreasing the FSH dose following step-up follicular selection may be an alternative method to avoid multifollicular development Key words: gonadotrophin therapy/ovarian hyperstimulation syndrome/polycystic ovarian syndrome/spontaneous abortion rate
Introduction
Ovulation induction in patients with polycystic ovarian syndrome (PCOS) is characterized by a risk of multiple follicular development resulting in a high incidence of multiple pregnancies and ovanan hyperstimulation syndrome (OHSS) (Wang and Gemzell, 1980) . In an attempt to reduce complication rates, Brown (1978) proposed a stepwise administration of gonadotrophins to establish the follicle-stimulating hormone (FSH) threshold required to induce follicular growth. Several studies have subsequently confirmed the ability of a chronic low-dose gonadotrophin administration schedule to reduce multifollicular development when compared with a conventional protocol (Seibel et al, 1984; Poison et al, 1987; Buvat et al, 1989; Shoham et al, 1991; Dale et al, 1993 , Homburg et al, 1995 . However, as the daily effective FSH dose is kept constant from the time of follicular selection until the criteria for the administration of human chorionic gonadotrophin (HCG) are reached, these regimens do not take into account the role of the physiological decrease in serum FSH concentrations during the late follicular phase. This decrease seems to be essential for dominance of the leading follicle and atresia of the remaining cohort of follicles allowing monofollicular ovulation (Van Santbrink et al., 1995) . Indeed it has been shown that the leading follicle can continue to mature m the presence of FSH concentrations unable to support the growth of less mature follicles (Zeleznik and Kubik, 1986) . The FSH threshold required for full follicular maturation during the second part of the follicular phase is still partly unknown. In this period of the cycle, extra FSH support acts through an acceleration of the growth rate of second-and third-in-order follicles to that of the dominant follicle without affecting the latter rate of growth (Lolis et al., 1995) . Therefore it may be postulated that maintaining FSH concentrations during the late follicular phase of the step-up protocol disturbs the dominance process and increases the risk of multifollicular development This concept is also supported by another report, that decreasing the gonadotrophin dose (i.e. the step-down protocol) after presumed follicular selection allows a reduction in mean FSH concentrations and in the number of medium-sized follicles during the late follicular phase (Schoot et al., 1992) . Thus the aim of this study was to evaluate, in patients with PCOS, both the effectiveness and safety of a sequential protocol combining an initial step-up gonadotrophin administration followed by a step-down regimen after presumed follicular selection. This protocol was prospectively compared with a low-dose step-up scheme of FSH administration.
Materials and methods
A total of 56 women with anovulatory infertility (World Health Organization Scientific Group Report, 1973 ; group 2) associated with PCOS were included in this study. PCOS was defined as chronic anovulation, typical ultrasound findings (>10 follicles <9 mm in diameter within each ovary, a hyperechogenic central stroma, ovarian area >8 cm 3 ; Adams et al., 1985) , a high serum luteinizing hormone (LH):FSH ratio and serum androgens (androstenedione and/or testosterone) All had failed to ovulate or to become pregnant with J.-N.Hugues et aL Values are mean ± SEM clomiphene citrate therapy. Normal male partner sperm parameters and a normal hysterosalpingogram were prerequisites for admission to the study. Patients were randomly allocated to one of the two regimens.
Low-dose step-up protocol (group 1)
A total of 38 cycles were started with one 75 IU ampoule of urinary human FSH (Metrodin; Serono, Boulogne, France) from day 3 of a spontaneous or progestogen-induced cycle for 6 days. The FSH dose was increased by half an ampoule (37.5 IU) every 6 days until the leading follicle reached 10 mm in diameter. Thus the same dose (i.e. the threshold dose) was maintained until the criteria for triggering ovulanon (at least one follicle >18 mm in diameter) were achieved. At that time, 5000 IU HCG (Gonadotrophin Endo; Organon, SaintDenis, France) were given to induce ovulation. No further HCG was added to support the luteal phase The injection of HCG was withheld if more than three follicles >15 mm in diameter were present.
Sequential low-dose step-up and step-down protocol (group 2)
A total of 35 cycles were conducted in a similar way, except that when the leading follicle reached 14 mm in diameter the FSH dose was reduced by half until the time of HCG administration.
Ovarian response was monitored 6 days after the initiation of therapy and every 2-3 days thereafter by vaginal ultrasound examination of the ovaries and measurement of serum oestradiol, LH and progesterone concentrations A serum sample for oestradiol and progesterone analysis was taken 5 days following HCG administration.
Statistical analysis
For a statistical analysis of the results, an unpaired Student's Mest and a one-way analysis of variance were performed when appropriate. P < 0.05 was considered to be statistically significant All reported data are expressed as mean ± SEM.
Results
In all, 73 cycles were initiated but four were cancelled: three because of ovarian hyperstimulation and one because of vaginal bleeding; three were randomized for a step-up protocol, and the last for a sequential protocol. These cycles were not included in the statistical analysis.
For the 52 women who completed the study, a comparison of clinical and endocrine features between women who received the step-up protocol and those who received the sequential protocol did not show any significant difference (Table I) .
Considering follicular development before the reduction in the FSH dose was performed in group 2, it appeared that the mean FSH threshold dose and the time required for follicular selection were similar in both groups (Table II) . At the time of the reduction in the FSH dose in group 2 (at least one follicle > 14 mm in diameter), no statistical difference existed in the mean number of medium-sized (10-13 mm) or larger (>14 mm) follicles and in the mean oestradiol concentrations when comparing both treatment groups. Ovarian response to both regimens is compared in Table II . Although the FSH daily effective dose was significantly lower in women treated with the sequential protocol (0.82 ± 0.05 versus 1.44 ± 0.05 ampoules; P < 0.0001), the length of the follicular phase was similar in both treatment groups. The most relevant differences between the step-up and sequential treatments were the mean number of large (14-15 mm) follicles (0 8 ± 0.2 and 0.3 ± 0.1 respectively; P = 0.05) and the mean oestradiol concentrations (593 ± 67 and 434 ± 45 pg/ ml respectively; P < 0.05) at the time of HCG administration. The mean number of small follicles was lower and the frequency of development of only one follicle >16 mm in diameter was higher in group 2, but these differences did not reach statistical significance.
Considering the luteal phase and the outcome of the cycles (Table HI) , serum progesterone concentrations were similar in both treatment groups but serum oestradiol concentrations were significantly lower in women treated with the sequential regimen. In all, 35 pregnancies were achieved: 20 in the stepup group and 15 in the sequential group. However, as there were eight (40%) and three (15%) miscarriages respectively, the rates of ongoing pregnancy were identical (~35% per cycle) in both treatment groups. No clinical OHSS was observed in any group.
Discussion
The aim of this study was to evaluate whether titrating the exogenous FSH dose more closely to the physiological pattern seen in spontaneous cycles altered the degree of follicular development. The study was undertaken in patients with PCOS, who are particularly at risk of multiple follicular development. In this situation, a chronic low-dose gonadotrophin administration has been used successfully to reduce the ovarian follicular response. However, by maintaining the same dose of gonadotrophin throughout the late follicular phase, such a regimen does not take into account the physiological decrease in serum FSH which seems to be essential to achieve monofollicular development (Van Santbrink et al., 1995) . The significant negative correlation between FSH and oestradiol concentrations indicates that late follicular phase oestradiol production may be stimulated to a greater extent in women with a slower decrease in FSH (Van Santbrink et al., 1995) . Thus the magnitude of oestradiol biosynthesis is closely related to the extent of FSH accumulation during the late follicular phase (Ben-Rafael et al, 1986) , and the size of the FSH rise determines ovarian hyperstimulation (Benadiva et al., 1988) .
In our study, the initial low-dose FSH administration was performed in both groups according to a step-up regimen, but with a shorter interval (6 days) than that described in the Values are means ± SEM HCG = human chononic gonadotrophin, NS = not significant chronic protocol (14 days) (Poison et al, 1987; HarrultonFairley et al., 1991) , so as to achieve more promptly the FSH threshold and to investigate the effects of a subsequent reduction of FSH supply. Our results show that a sequential FSH administration with a successive step-up and step-down scheme results in a slight but significant reduction in the size of the foUicular cohort by lowering the number of secondand third-in-order follicles. They agree with a previous report (Rabinovici et al., 1987) showing that cycles prone to developing ovarian hyperstimulation could be rescued by withholding gonadotrophin supply for several days. They are also in agreement with other studies where the degree of ovarian stimulation was positively correlated with pre-ovulatory serum FSH concentrations (Van der Meer et al., 1994) . Using a decremental dose regimen, Schoot et al. (1992) were able to mimic the physiological FSH serum decrease in the late follicular phase and to induce the maturational arrest of functional medium-sized follicles. Although serum FSH determinations throughout stimulation were not performed in our study, we may presume that the observed reduction in the number of secondary follicles is related to the lower dose of FSH administered during the late follicular phase. Moreover, the similar duration of the follicular phase in both protocols indicates that lowering the FSH dose during the late follicular phase is not detrimental for the final maturation of the dominant follicle. This observation agrees with the concept that the rate of growth of the dominant follicle is largely independent of gonadotrophin concentrations in this period of the cycle (Templeton et al., 1986) . Thus the slightly lower serum oestradiol concentrations observed at the time of HCG injection in patients treated with the sequential protocol may be related to the decrease in the number of medium-sized follicles, suggesting that relatively low FSH concentrations result in maturational arrest of the non-leading follicles. As far as the luteal phase is concerned, our results show a similar increase in serum progesterone concentrations, testifying that the reduction in FSH supply during the late follicular phase does not alter the ability of embryos to implant. However, serum oestradiol luteal concentrations were significantly decreased in patients treated with the sequential protocol. As serum LH concentrations were similar at the time of HCG administration, an inappropnate support of the corpus luteum is unlikely. We suggest that lower luteal oestradiol concentrations indicate a quantitative reduction in the aromatase activity of luteal cells which may be related to the lower number of follicles observed at the tune of HCG administration. No severe clinical hyperstimulation syndrome was observed in this study whichever the protocol used. This could be explained by our design where HCG injection was cancelled in patients with more than three large follicles.
A surprising feature of this study was the relatively low incidence of miscarriages in patients treated with the sequential protocol. Early pregnancy loss is frequently observed in PCOS patients and does not seem to be prevented by using chronic low-dose step-up FSH stimulation (Hamilton-Fairley et al., 1991) . Brzyski et al. (1995) recently suggested that the slight increase in the serum androgen:oestradiol ratio associated with this regimen may adversely affect oocyte quality and explain the relatively high miscarriage rate. As serum LH concentrations were similar in both treatment groups, it was proposed that ovarian androgens, rather than LH itself, might mediate the development of pregnancy wastage in PCOS. Although thecal cell androgen production is largely dependent on LH secretion, it has been shown that FSH may also contribute to androgen output through a paracrine mechanism: both inhibin and immunoglobulin Fl produced by granulosa cells are able to stimulate in-vitro androgen secretion by human thecal cells (Hillier et al, 1991) . Therefore we would rather suggest that decreasing the FSH dose supply during the late follicular phase, as performed with the present sequential protocol, may lower androgen production and therefore reduce the incidence of miscarriage. A comparative study is now in progress to test this hypothesis.
Finally another issue of this study would be to examine at which stage of follicular development it seems appropriate to reduce exogenous FSH supply to obtain monofollicular growth. In the present protocol, we decided to reduce the FSH dose when the largest follicle reached a diameter of 14 mm because growing follicles could definitively be identified on ultrasound at this stage of development. However, as the selection of the dominant follicle occurs earlier in the cycle (Pache et al, 1990) and because of the relatively long half-life of FSH after parenteral administration (Porchet et al, 1994) , it would be more appropriate to reduce the daily FSH dose when the selected follicle emerges from the cohort, i.e. at a size of 10 mm in diameter. As shown by Lolis et al. (1995) , the final number of pre-ovulatory follicles is determined by the extra FSH supply during the mid-and late follicular phases. Whether reducing the FSH dose earlier will help to increase further the rate of monofollicular development is being tested in a new prospective study.
